- Home
- PTC vs BIIB Comparison
PTC vs BIIB Comparison
Compare PTC & BIIB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PTC
- BIIB
- Stock Information
- Founded
- PTC 1985
- BIIB 1978
- Country
- PTC United States
- BIIB United States
- Employees
- PTC N/A
- BIIB N/A
- Industry
- PTC Computer Software: Prepackaged Software
- BIIB Biotechnology: Pharmaceutical Preparations
- Sector
- PTC Technology
- BIIB Health Care
- Exchange
- PTC Nasdaq
- BIIB Nasdaq
- Market Cap
- PTC 20.2B
- BIIB 18.7B
- IPO Year
- PTC 1989
- BIIB 1991
- Fundamental
- Price
- PTC $203.98
- BIIB $144.87
- Analyst Decision
- PTC Buy
- BIIB Buy
- Analyst Count
- PTC 13
- BIIB 27
- Target Price
- PTC $209.77
- BIIB $188.09
- AVG Volume (30 Days)
- PTC 802.0K
- BIIB 1.5M
- Earning Date
- PTC 11-05-2025
- BIIB 10-29-2025
- Dividend Yield
- PTC N/A
- BIIB N/A
- EPS Growth
- PTC 73.27
- BIIB 31.67
- EPS
- PTC 4.25
- BIIB 10.45
- Revenue
- PTC $2,471,978,000.00
- BIIB $9,997,000,000.00
- Revenue This Year
- PTC $13.86
- BIIB $2.00
- Revenue Next Year
- PTC $7.68
- BIIB N/A
- P/E Ratio
- PTC $47.93
- BIIB $13.83
- Revenue Growth
- PTC 11.42
- BIIB 3.36
- 52 Week Low
- PTC $133.38
- BIIB $110.04
- 52 Week High
- PTC $219.69
- BIIB $204.18
- Technical
- Relative Strength Index (RSI)
- PTC 43.19
- BIIB 60.19
- Support Level
- PTC $202.26
- BIIB $141.12
- Resistance Level
- PTC $208.56
- BIIB $147.23
- Average True Range (ATR)
- PTC 4.04
- BIIB 4.65
- MACD
- PTC -1.49
- BIIB 0.23
- Stochastic Oscillator
- PTC 11.18
- BIIB 71.16
About PTC PTC Inc.
PTC offers high-end computer-assisted design (Creo) and product lifecycle management (Windchill) software as well as Internet of Things and AR industrial solutions. Founded in 1985, PTC has 28,000 customers, with revenue stemming mostly from North America and Europe.
About BIIB Biogen Inc.
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.